Summary of Product Characteristics
last updated on the eMC:
01/02/2011
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 01/02/2011 and displayed until Current
|
Reasons for adding or updating:
|
-
Change to section 4.8 - Undesirable Effects
|
| Date of revision of text on the SPC: 10-Jan-2011 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
Underlined text has been added, text with strike through deleted:
4.8 Undesirable effects
There are only few unconfirmed reports of the occurrence of possible anaphylactoid reactions after intravenous injection of Konakion MM. There have been reports of anaphylactoid reactions after intravenous injections of Konakion MM. Very rarely, venous irritation or phlebitis has been reported in association with intravenous administration of Konakion mixed micelle solution. Injection site reactions have been reported after intramuscular injection of Konakion.
|
|
Updated on 25/02/2010 and displayed until 01/02/2011
|
Reasons for adding or updating:
|
-
Change to section 9 - Date of first Authorisation/renewal of the Authorisation
|
| Date of revision of text on the SPC: 08-Apr-2008 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| change to date of renewal
|
|
Updated on 05/12/2005 and displayed until 25/02/2010
|
Reasons for adding or updating:
|
|
|
|
Updated on 03/04/2003 and displayed until 05/12/2005
|
Reasons for adding or updating:
|
-
Change to section 6.1 - List of Excipients
|
|
Updated on 06/08/2001 and displayed until 03/04/2003
|
Reasons for adding or updating:
|
-
Transferred from eMC version 1
|
|
Updated on 06/09/1999 and displayed until 06/08/2001
|
Reasons for adding or updating:
|
|
|
|
